论文部分内容阅读
儿童炎症性肠病近年发病率逐渐升高，该病为慢性肠道炎症性疾病，其好发年龄为学龄期，严重影响患儿生长发育，同时给心理和精神上带来创伤。目前该病的病因及发病机制尚未明确，但随着近年来对肠道菌群的深入研究，表明肠道菌群失调在该疾病的发生、发展中起到重要作用，且在临床得到广泛证实。因此，人们尝试将微生态制剂应用于炎症性肠病患儿治疗中。该文主要综述炎症性肠病患儿应用益生菌、益生元、粪菌移植等微生态制剂治疗的研究进展，分析微生态制剂对炎症性肠病患儿的治疗效果，为临床提供新的思路。“,”The incidence of childhood inflammatory bowel disease has gradually increased in recent years.The disease is a chronic intestinal inflammatory disease, and its susceptible age is school age, which seriously affects the growth and development of children and brings psychological and spiritual trauma.The etiology and pathogenesis of inflammatory bowel disease is unclear, but with the in-depth study of the intestinal flora in recent years, it has been shown that intestinal flora imbalance plays an important role in the occurrence and development of the disease, and it has also been widely confirmed in clinical practice.Therefore, people try to use probiotics in the treatment of children with inflammatory bowel disease.This article mainly reviews the progress of the application of probiotics, prebiotics, fecal bacteria transplantation and other microecological agent in children with inflammatory bowel disease, analyzes the therapeutic effects of probiotics on children with inflammatory bowel disease, and provides new ideas for clinical practice.